We found that activation of several innate immunity pathways, a crucial step for the generation of adaptive anti-tumor responses [22] and for the efficacy of immune checkpoint blockade [23], characterized the immune-related transcriptional program specifically induced in melanoma cells by the DNMT inhibitor guadecitabine, compared to the other drugs. The gene discussed is DNMT1; the disease is melanoma.